Literature DB >> 7388793

Quantitation by gas chromatography-chemical ionization-mass spectrometry of phenylalanine mustard in plasma of patients.

S L Pallante, C Fenselau, R G Mennel, R B Brundrett, M Appler, N B Rosenshein, M Colvin.   

Abstract

An unambiguous and sensitive method based on gas chromatography-chemical ionization-mass spectrometry has been developed to quantitate L-phenylalanine mustard and has been applied to measure levels in plasma of five patients receiving 0.15 to 0.25 mg/kg (10 to 17 mg) of the drug p.o. Peak plasma levels of 50 to 190 ng/ml were found to occur between 0.7 and 2.3 hr after ingestion. The time for the plasma level to fall to one-half of the peak value varied from 0.6 to 3 hr, and very low levels (less than 2 ng/ml) were present by 24 hr.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7388793

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma.

Authors:  H K Osterheld; E Musch; G E von Unruh; U Loos; H Rauschecker; B J Mühlenbruch
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma.

Authors:  A G Bosanquet; E D Gilby
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases.

Authors:  C Ardiet; B Tranchand; P Biron; P Rebattu; T Philip
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Pharmacokinetics of high-dose melphalan in children and adults.

Authors:  A Gouyette; O Hartmann; J L Pico
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma.

Authors:  I A Taha; R A Ahmad; H Gray; C I Roberts; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.